BridgeBio Pharma price to sales ratio BBIO
Market value divided by revenue over the last twelve months, since 2021.
- Today, Nov 2, 2026
- 20.6×
- 5-year median
- 26.2×
- Against its 5-year history
- 22nd
- percentile: 0 is its lowest day, 100 its highest
- 5-year range
- 12.5× to 138×
- Peer median
- 6.5×
BridgeBio Pharma's price to sales ratio is 20.6× as of Nov 2, 2026.
That is below its 5-year median of 26.2×, lower than on 78% of days in the last 5 years.
Over that time it ranged from 12.5× in Jan 2023 to 138× in Nov 2021.
The median for 10 large drugmakers of a similar size is 6.5×.
Price to sales ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 20.6× | 17.9× | 42.6× |
| 2025 | 41.3× | 24.4× | 70.6× |
| 2024 | 24.3× | 20.3× | 26.3× |
| 2023 | 71.0× | 12.5× | 71.0× |
| 2022 | 12.8× | 12.8× | 37.9× |
| 2021 | 43.1× | 43.1× | 138× |
Against its peers
Companies in Drug Manufacturers - General nearest BridgeBio Pharma's size, closest first, today.
| Company | Price to sales ratio |
|---|---|
| BBIOBridgeBio Pharma | 20.6× |
| JAZZJazz Pharmaceuticals | 3.0× |
| BMRNBiomarin Pharmaceutical | 3.3× |
| TGTXTG Therapeutics | 11.5× |
| PTGXProtagonist Therapeutics | 32.0× |
| CORTCorcept Therapeutics | 10.5× |
| ALKSAlkermes plc. | 4.5× |
| KNSAKiniksa Pharmaceuticals International | 8.4× |
| AMRXAmneal Pharmaceuticals | 2.1× |
| LGNDLigand Pharmaceuticals | 21.1× |
| BIIBBiogen | 3.7× |
| Peer median | 6.5× |
What the price to sales ratio tells you
Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.
Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.
More on BridgeBio Pharma
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.